Tyme Technologies, Inc. (TYME)
(Delayed Data from NSDQ)
$1.56 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.56 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.56 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.56 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Biotech Stock Roundup: VRTX's Regulatory Update, TYME Gains on Acquisition & More
by Zacks Equity Research
Regulatory and other updates from Vertex (VRTX) and TYME are a few key highlights from the biotech sector during the past week.
Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study
by Zacks Equity Research
Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.
Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up
by Zacks Equity Research
Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.
Lilly's Pancreatic Cancer Candidate Fails in Phase III Study
by Zacks Equity Research
Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.
Tyme Initiates Pivotal Stage of Pancreatic Cancer Study
by Zacks Equity Research
Tyme (TYME) initiates the pivotal stage of the TYME-88-Panc study evaluating oral SM-88 (racemetyrosine) for third-line treatment of patients with metastatic pancreatic cancer.
Will Tyme Technologies Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Tyme Technologies.
Will Tyme Technologies Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Tyme Technologies.
Tyme Technologies Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Tyme Technologies, Inc. (TYME) has been struggling lately, but the selling pressure may be coming to an end soon.
Tyme Technologies (TYME) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Tyme Technologies, Inc. (TYME).
Tyme Technologies Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Tyme Technologies has been struggling lately, but the selling pressure may be coming to an end soon.